Patents by Inventor Joseph A. Borkowski

Joseph A. Borkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA encoding bradykinin B1 receptor
    Publication number: 20030036633
    Abstract: DNAs encoding bradykinin B1 receptors from mammalian cells have been cloned and characterized. The recombinant receptor is capable of forming receptors which bind des-Arg10 kallidin and other B1-specific ligands. The DNA has been expressed in recombinant host cells which produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
    Type: Application
    Filed: October 22, 2001
    Publication date: February 20, 2003
    Applicant: Merck & Co., Inc.
    Inventors: David L. Linemeyer, John W. Hess, Joseph A. Borkowski, Kathleen K. Bierilo, John G. Menke
  • Cloned and expressed human bradykinin BK-2 receptor
    Patent number: 6407207
    Abstract: The present invention is a cloned human BK-2 bradykinin receptor cloned from a human lung fibroblast cell line. A cDNA clone, also part of the instant invention, encodes a novel 364 amino acid protein (the BK-2 receptor) that has the characteristics of a seven transmembrane domain G-protein coupled receptor. The invention is used to express a BK-2 bradykinin receptor in a host mammalian cell to screen for pharmaceutical antagonists or agonists which bind to or interact with the BK-2 bradykinin receptor protein.
    Type: Grant
    Filed: November 8, 1993
    Date of Patent: June 18, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Joseph A. Borkowski, John W. Hess, Catherine D. Strader, Richard W. Ransom
  • Bradykinin B1 receptor antibodies
    Patent number: 6307027
    Abstract: DNAs encoding bradykinin B1 receptors from mammalian cells have been cloned and characterized. The recombinant receptor is capable of forming receptors which bind desArg10 kallidin and other B1-specific ligands. The DNA has been expressed in recombinant host cells which produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: October 23, 2001
    Assignee: Merck & Co., Inc.
    Inventors: David L. Linemeyer, John W. Hess, Joseph A. Borkowski, Kathleen K. Bierilo, John G. Menke
  • Purified bradykinin B.sub.1 receptor
    Patent number: 5965367
    Abstract: DNAs encoding bradykinin B.sub.1 receptors from mammalian cells have been cloned and characterized. The recombinant receptor is capable of forming receptors which bind des-Arg.sup.10 kallidin and other B.sub.1 -specific ligands. The DNA has been expressed in recombinant host cells which produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
    Type: Grant
    Filed: September 17, 1997
    Date of Patent: October 12, 1999
    Assignee: Merck & Co., Inc.
    Inventors: David L. Linemeyer, John W. Hess, Joseph A. Borkowski, Kathleen K. Bierilo, John G. Menke
  • Bradykinin B2 receptor modified transgenic non-human animals
    Patent number: 5750826
    Abstract: A transgenic non-human animal with alterations in a bradykinin B2 receptor gene is prepared by introduction of a gene encoding an altered bradykinin B2 receptor into a host non-human animal.
    Type: Grant
    Filed: December 2, 1996
    Date of Patent: May 12, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Joseph A. Borkowski, Howard Y. Chen, John W. Hess, Catherine D. Strader, Myrna E. Trumbauer
  • DNA encoding bradykinin B1 receptor
    Patent number: 5712111
    Abstract: DNAs encoding bradykinin B.sub.1 receptors from mammalian cells have been cloned and characterized. The recombinant receptor is capable of forming receptors which bind des-Arg.sup.10 kallidin and other B.sub.1 -specific ligands. The DNA has been expressed in recombinant host cells which produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
    Type: Grant
    Filed: April 15, 1994
    Date of Patent: January 27, 1998
    Assignee: Merck & Co., Inc.
    Inventors: David L. Linemeyer, John W. Hess, Joseph A. Borkowski, Kathleen K. Bierilo, John G. Menke